Reference studies for strontium ranelate in the treatment of osteoporosis

Introduction Strontium ranelate is an agent used for the treatment of osteoporosis. It consists of two atoms of stable strontium and an organic part: ranelic acid. Simultaneously, it stimulates the formation of new bone and reduces bone resorption, resulting in a deviation from the balance of bone turnover towards formation. These actions are effected by improving the replication of pre-osteoblastic cells and the differentiation of osteoblasts, as well as reducing their capacity to induce the osteoclasts through the receptor sensors of calcium (CaR) and increase the range OPG/RANKL. Its effectiveness in animals has been widely studied, it having been shown to augment bone mass in osteopenic animals, to prevent bone loss in ovaryectomised rats and to increase bone resistance in normal animals. The action mechanism of strontium ranelate, as well as its effect on bone quality, is studied in greater detail in other chapters of this monograph.